|
Mr. Kelley brings over 25 years of entrepreneurial venture capital operational and technical biotechnology experience to Halozyme. Mr. Kelley has been the managing director of K2 Bioventures a biomedical startup consulting company since July 2004. From April 2002 through June 2004 Mr. Kelley was a General Partner at Latterell Venture Partners where he made investments in early stage biotechnology and medical device startups. Mr. Kelley founded IntraBiotics Pharmaceuticals in January 1994 and over eight years served as CEO Director and Chairman. Earlier Mr. Kelley was an Associate at Institutional Venture Partners (IVP) where he participated in the financing of twenty biotech and medical companies fifteen of which became public companies. Prior to IVP he was a consultant for McKinsey & Company and a scientist at Integrated Genetics (acquired by Genzyme). Mr. Kelley earned an M.B.A. from Stanford University and a B.A. in biochemical sciences from Harvard University. Mr. Kelley is the Chairman of the Board of Directors and serves on the Audit Committee and Compensation Committee. | 